Importantly, TGFβ-associated pathways emerged as relevant signaling in patients who were non responsive to anti–programmed cell death-1 (PD-1) therapy in both melanoma and metastatic urothelial cancer [110,111]. Here, TGFB1 is linked to melanoma.